Please assess the completion status of the following clinical trial:

Trial Title: Safety of Intravenous Lacosamide Dose Followed by Twice Daily Oral Lacosamide in Subjects With Partial-onset Seizures

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of epilepsy with simple partial seizures and/or complex partial seizures~* Stable dose regimen of 1 to 2 marketed antiepileptic drug(s) (AED(s)) for 28 days prior to screening and duration of trial~* Acceptable candidate for venipuncture and intravenous (iv) infusion~* At least 1 partial seizure with motor component per 90 days~* Maximum allowed seizure frequency during 28 days prior to screening is 40 partial seizures of any type~Exclusion Criteria:~* Previous use of lacosamide~* History of primary generalized seizures~* History of status epilepticus within last 12 months~* History of cluster seizures during 8 week period prior to screening~* Non-epileptic events, including psychogenic seizures that could be confused with seizures~* Use of neuroleptics, monoamine oxidase (MAO) inhibitors, barbiturates, or narcotic analgesics within 28 days prior to screening~* Received any rescue benzodiazepines more than once during the 28 days prior to screening~* Concomitant treatment of felbamate or previous felbamate therapy within last 6 months~* Prior or concomitant vigabatrin use

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Lacosamide 200 mg cohort (Type: EXPERIMENTAL): Single loading dose of intravenous (iv) lacosamide 200 mg followed by 6.5 days of oral lacosamide 100 mg twice daily
- Lacosamide 300 mg combined cohorts (Type: EXPERIMENTAL): Single loading dose of intravenous (iv) lacosamide 300 mg dose followed by 6.5 days of oral lacosamide 150 mg twice daily
- Lacosamide 400 mg cohort (Type: EXPERIMENTAL): Single loading dose of intravenous (iv) lacosamide 400 mg followed by 6.5 days of oral lacosamide 200 mg twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).